To examine the efficacy of ultrasound-mediated gene therapy in the treatment of hepatic cancer, we performed cationic liposomemediated interferon-b (IFNb) gene therapy combined with sonoporation, using metastatic hepatic tumors of murine colon cancer. The combination of liposome/DNA treatment and ultrasound gave higher transgene IFNb expression in Colon26 colon adenocarcinoma cells than that with microbubble/DNA in combination with ultrasound and that with liposome/DNA alone. Cationic liposome-mediated IFNb gene therapy combined with ultrasound showed an antitumor effect in vitro and combination use of the anticancer drug cis-diamminedichloroplatinum (CDDP) showed a synergistic effect with the IFNb gene therapy. The survival of mice with metastatic hepatic tumor of Colon26 cells was significantly prolonged by cationic liposome-mediated IFNb gene therapy alone, and sonoporation had a synergistic effect on prolongation of survival and inhibition of tumor growth rate in these mice. Combination use of CDDP with IFNb gene therapy also showed a synergistic effect on prolongation of survival and inhibition of tumor growth rate. In conclusion, ultrasound-mediated gene therapy for the treatment of hepatic cancers may be effective in a clinical setting.
Introduction
Ultrasound is a common diagnostic tool for disorders of the heart and liver, and has a considerable potential for gene transduction into cells and tissues. 1 Ultrasound can induce temporary micropores in the membranes of target cells, through which DNA can then pass, and the DNA is trapped in the cells following re-sealing of the membrane. 2 This phenomenon, which is referred to as sonoporation, is enhanced by the use of microbubble echo-contrast agents and the augmentation of acoustic cavitation. 3 It has been reported that the effect of ultrasound in mediating gene transfer is also upregulated by DNA entrapment in liposomes. 4, 5 Hepatic cancers such as hepatocellular carcinoma and secondary hepatic metastases are abdominal malignancies with a particularly poor prognosis, and are usually treated by surgical resection, chemotherapy and various ablation therapies such as ethanol injection, microwave coagulation and radiofrequency ablation. However, recurrence rates are very high due to latent virus infection or micrometastasis in the liver. It has been reported that gene therapy using viral and nonviral vectors is a most promising method for multiple or non-curative hepatic cancers, through cytokine gene therapy, suicide gene therapy and tumor-suppressor gene therapy. 6 Recent investigations have shown that a replication-competent adenovirus, called ONYX, can be safely used by intraarterial injection into the hepatic artery, compared to replication-deficient adenoviruses. 7 However, due to the high risk of acute inflammatory responses after systemic injection of viruses, the development of an effective therapy using a non-viral vector would be of value for hepatic cancers. 8 Thus, in this study, we examined the effect of sonoporation on cationic liposome-mediated interferon-b (IFNb) gene therapy for treatment of metastatic hepatic tumors of murine colon cancer.
Materials and methods

Cells and animals
Murine colon cancer cell line Colon26 and Balb/c mice (8 weeks old, male) were used in the experiments. The animals were purchased from Chubukagaku, Japan, and maintained according to the rules of the animal department of Nagoya University.
Genes
Plasmids encoding green fluorescent protein (GFP) and LacZ cDNAs were purchased from RikenGene Bank, Japan. Transcription of GFP cDNA was driven by a cytomegalovirus promoter, whereas that of LacZ cDNA was driven by a CAG hybrid promoter. A plasmid carrying hIFNb cDNA (pDRSV-hIFNb, 3674 bp) was prepared as described in a previous paper.
9 Microbubble (BR14) was supplied by Bracco Research Inc., Princeton, NJ.
Liposome preparation
Entrapment of plasmid pDRSV-hIFNb in cationic multilamellar liposomes composed of positively charged lipids TMAG, DLPC and DOPE in a molar ratio of 1:2:2 was achieved as described previously. 9 The therapeutic agent, comprising cationic multilamellar liposomes containing hIFNb cDNA, is designated hereafter as 'IAB-1'. A lyophilized preparation of IAB-1, in which sucrose was included as a preservative, was used in the present study. The lyophilized agent was stable for at least 6 months in terms of restoration of the intact plasmid, its bioactivity in producing IFNb in test cells and the particle size of the liposomes. Lyophilized IAB-1 containing 100 mg of DNA and 5 mmol of total lipids in a vial was rehydrated by the addition of 1 ml of sterilized distilled water before use, and then diluted with sterile phosphate-buffered saline to give the desired concentrations of plasmid DNA. The plasmids encoding GFP and LacZ cDNA were entrapped in cationic multilamellar liposomes as described above. 10 Ultrasound-mediated gene transfer In the in vitro experiments, 1 Â 10 6 cells per well were applied to 48-well microplates. Following mixing of the liposome/DNA or microbubble/DNA, the microplates were then irradiated with ultrasound using a Sonitron 1000 (Rich-Mar Corp., OK), at 1 MHz input frequency and 0.5 W cm À2 output intensity, with a duty cycle of 20% and a 30-s exposure time.
In the in vivo experiments, the abdomens of Balb/c mice were midline-opened and 1 Â 10 6 Colon26 cells were directly injected into the left lobe of the liver. Seven days after injection, 2.5 mg per 100 ml of liposome/IFNb was directly injected into the newly formed hepatic tumor, which was then directly irradiated with ultrasound, using contact gel, at 1 MHz input frequency and 2.0 W cm À2 output intensity, with a duty cycle of 50% and a 10-min exposure time.
In vitro experiments Transgene expression. After the cells were transfected by ultrasound-mediated gene transfer, they were incubated for 24 h and then used in the following assays. LacZ expression in the cells was detected by the X-gal staining method. Briefly, the transduced cells were cultured overnight, and then incubated with a solution containing X-gal (400 mg ml À1 ), 5 mM potassium ferriferrocyanide and 1 mM MgCl 2 at 37 1C for 24 h. GFP expression was analyzed by fluorescence-activated cell sorting, and IFNb secretion in supernatants collected from the cells for 24 h was measured using a HuIFNb ELISA kit (Fujirebio Inc., Tokyo, Japan).
MTT assay. The antitumor effect of IFNb gene transfer and the effect of an anticancer agent (cis-diamminedichloroplatinum, CDDP) were analyzed by MTT assay using a Cell Growth Kit (Chemicon Co., CA). Briefly, after the cells were transfected by ultrasound-mediated gene transfer, 5 Â 10 3 cells per well were cultured in 96-well microplates for 24 h. After replacing the Dulbecco's modified Eagle's medium with 10% fetal calf serum, the cells were cultured for 48 h with or without CDDP, and then subjected to the MTT assay.
In vivo experiment
The animals were first divided into a group that received an injection of CDDP (5 mg kg À1 ) intraperitoneally 3 days before gene transduction (CDDP( þ )), and a group that did not receive CDDP (CDDP(À)). These groups were then further divided into six groups as follows:
After gene transduction to the hepatic tumor, the survival of mice was checked daily. In addition, 7 days after gene transduction, tumors were dissected and their size was measured to assess the tumor growth rate. Liver specimens were examined by hematoxylin and eosin staining.
Statistical analysis
Data were expressed by mean ± s.d. Statistical differences were analyzed by a Mann-Whitney U-test using StatView 5.0, and significance was defined as Po0.05.
Results
Transgene expression
To confirm transgene expression in the colon cancer cell line Colon26, the level of ultrasound-mediated gene transfer using either the liposome/DNA method or the microbubble/DNA method was compared (Figure 1 ). With the microbubble/DNA method, a maximum of 5% of the cells expressed GFP protein when 40 mg of DNA with 20 ml of microbubble (BR14) was added to Colon26 cells with ultrasound irradiation (mean±s.d.; 3±2%). With the liposome/DNA method, a maximum of 21% of the cells expressed GFP protein when 1 mg of liposome/ DNA was added to Colon26 cells with ultrasound irradiation (mean ± s.d.; 18 ± 3%). Delivery of 2.5 mg of liposome/DNA was also attempted using ultrasound, but this amount of DNA proved to be toxic to the cells. When Colon26 cells were transfected with 1 mg of liposome/ DNA using ultrasound, the IFNb production for 24 h ranged from 11.5 to 13.9 (11.5, 12.8 and 13.9) IU ml Cell cytotoxicity using ultrasound-mediated IFNb gene therapy and the anticancer drug CDDP in vitro The cytotoxic effect of ultrasound-mediated IFNb gene therapy on Colon26 cells was analyzed with or without combination use of CDDP. Liposome/IFNb transduction without ultrasound reduced the cell viability to 75 ± 8 and 73±7% with 1 and 2.5 mg of liposome/IFNb, respectively, whereas ultrasound-mediated transduction of liposome/ IFNb reduced the cell viability to 62 ± 7 and 56 ± 9% with 1 and 2.5 mg of liposome/IFNb, respectively. When CDDP was added to the cell culture, the cell viability was dose dependently suppressed to 78 ± 7, 58 ± 8 and 47 ± 8% by 0.1, 0.5 and 1.0 mg ml À1 CDDP, respectively. Using 1.0 mg of liposome/IFNb, the synergistic effect of ultrasound-mediated IFNb gene therapy and CDDP treatment was examined. Combination use of CDDP and ultrasound-mediated IFNb gene therapy significantly suppressed cell viability to 53 ± 9, 35 ± 5 and 13 ± 4% with 0.1, 0.5 and 1.0 mg ml À1 CDDP, respectively ( Figure 2 ).
Survival of mice with hepatic metastasis and antitumor effect of ultrasound-mediated IFNb gene therapy and CDDP in vivo Finally, the in vivo effects of ultrasound-mediated IFNb gene therapy and CDDP were examined in mice with hepatic metastasis of colon cancer. To establish the mouse model of hepatic metastasis, Colon26 cells were injected into the left lobe of the liver. Seven days after injection, the tumor that developed was directly irradiated with ultrasound just after injection of liposome/IFNb.
The mean survival time for mice with hepatic metastasis was 24.6 days without treatment (n ¼ 10), and this was significantly increased to 42.2 days with liposome/IFNb gene therapy alone (n ¼ 10), and to 49.2 days with ultrasound-mediated liposome/IFNb gene therapy (n ¼ 10). The tumor growth rate (tumor size 14 days after cell injection/tumor size 7 days after cell injection) was 21.5 ± 4.0 in the control group (n ¼ 5), 5.0 ± 2.6 in the liposome/IFNb gene therapy group (n ¼ 5) and 3.0 ± 2.1 in the ultrasound-mediated liposome/IFNb gene therapy group (n ¼ 5) (Figure 3a) .
With CDDP, the mean survival time for mice with hepatic metastasis was 35.8 days (n ¼ 10), compared to 24.6 days for the control group. Combination use of CDDP and gene therapy significantly increased the mean survival time to 49.6 days with CDDP and liposome/ IFNb gene therapy alone (n ¼ 10), and to 59.8 days with CDDP and ultrasound-mediated liposome/IFNb gene therapy (n ¼ 10). The tumor growth rate was 6.9 ± 3.8 with CDDP alone (n ¼ 5), 2.3±1.2 with CDDP and liposome-IFNb gene therapy (n ¼ 5), and 1.1 ± 0.8 with CDDP and ultrasound-mediated liposome/IFNb gene therapy (n ¼ 5) (Figure 3b) .
Histopathological findings showed diffuse cancer tissues and spotty fibrous tissues in the hepatic metastasis of colon cancer in untreated animals, and reduced cancer tissue and hemorrhagic necrotic tissue in those animals that underwent ultrasound-mediated liposome/ IFNb gene therapy. Many apoptotic cells were observed in samples from animals that underwent ultrasound-mediated liposome/IFNb gene therapy (data not shown).
Discussion
The most important problems associated with gene therapy technique in a clinical setting are efficiency of gene transduction, target selectivity and safety of the vector. It is well known that non-viral vectors are relatively safe, but their gene-transduction efficiency and target selectivity remain to be determined. Cationic liposomes are one of the most interesting non-viral vectors for human gene therapy, because of their high transduction efficiency compared to the other non-viral vectors. Morphologically, cationic liposomes are divided into three types: small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. 11, 12 Of these types, multilamellar vesicles generally entrap genes most efficiently within the liposomes, and are characterized by high stability and good transduction efficiency. IAB-1 is composed of cationic multilamellar liposomes containing the human IFNb gene, and a clinical trial using IAB-1 for malignant brain tumor has started in Japan. 13 However, it remains to be determined whether the cationic liposome possesses selectivity for transduction to the target, especially following intravenous or intra-arterial injection.
Recent investigations have shown that ultrasound augments transduction efficiency to the target, due to 
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S Hayashi et al micropore formation and a cavitation effect, especially in combination use with either microbubbles or liposomes. 14, 15 Ultrasound is commonly applied to the diagnosis of hepatic tumor, and in liver surgery, an intraoperative ultrasound test is routinely used to identify the major hepatic vessels and establish the position of the tumor accurately. The present study demonstrated that ultrasound-mediated gene transfer using a liposome has a high transduction efficiency in a colon cancer cell line, compared to that using a microbubble, and that ultrasound augments the transduction efficiency of a liposome/ DNA complex, compared to use of the liposome/DNA complex alone. It has been reported that microbubbles augment the transduction efficiency of ultrasoundmediated gene transfer in various cell lines and various organs, and we have previously shown that ultrasoundmediated gene transfer with microbubbles is useful for gene therapy of human hepatocellular cancers. 16 The microbubble used in the present study was manufactured independent of the DNA and does not entrap the DNA, in contrast to the liposome, and this difference may influence the transduction efficiency in ultrasoundmediated gene transfer.
The in vitro experiments in colon cancer cells showed that the cytotoxicity of ultrasound-mediated IFNb/liposome gene transfer is synergistically augmented by combination use of the anticancer drug CDDP. In particular, the addition of 1.0 mg ml À1 of CDDP dramatically promoted cell death in ultrasound-mediated IFNb/ liposome gene transfer. It has been reported that IFNb/ liposome gene transfer shows significant antitumor activity in various cell lines, including glioma, malignant melanoma and renal cell carcinoma. 10, [17] [18] [19] The antitumor activity in the Colon26 cells was comparatively low, compared to that observed in the above cell lines using the IFNb/liposome complex alone, 20, 21 but ultrasound enhanced the transduction efficiency of the liposome/DNA complex, and this combination may be applicable to cancer gene therapy for many kinds of cancer. Previous investigations have demonstrated that CDDP can enhance the antitumor effect of gene therapy, partly because of upregulation of transgene expression, 22 and it has recently been reported that IFN treatment of hepatocellular carcinoma can augment antitumor activity in combination use with 5-FU, due to the acceleration of apoptotic cell death. 23 These findings suggest that IFNb gene therapy combined with an anticancer drug regimen is a rational strategy for the treatment of hepatic cancers such as hepatocellular carcinoma and metastatic hepatic carcinoma. 24 Consistent with the in vitro data, in vivo experiments clearly demonstrated that ultrasound-mediated IFN/ liposome gene therapy prolonged the survival of mice with hepatic metastasis of colon cancer, with the effect being dependent on the combination use of CDDP. No reduction in tumor size was observed in most animals that underwent ultrasound-mediated IFN/ liposome gene therapy alone, but tumor growth inhibition was clearly observed in those animals that received ultrasound-mediated IFN/liposome gene therapy with CDDP. In vivo, the liver tumor was irradiated with ultrasound immediately after a direct injection of the IFN/liposome into the tumor. The strength and duration of the irradiation were higher than those used in the in vitro experiments, but this technique of gene transfer to hepatic cancers is feasible for a clinical setting. 
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Previous papers have shown that ultrasound-mediated gene transfer may allow transgene expression in tumors following intravenous injection of a liposome/DNA complex, 25 but it remains to be determined whether transgene expression in hepatic cancers can be induced by ultrasound irradiation combined with systemic injection of the liposome/DNA complex. Our results show that selective and enhanced gene transfer to tumors may be feasible using ultrasound irradiation combined with direct injection of the liposome/DNA complex, but further studies are required to determine the best route of liposome/DNA complex administration in ultrasoundmediated gene therapy for hepatic cancers. 
